gamma-aminobutyric acid has been researched along with Pain, Intractable in 32 studies
gamma-Aminobutyric Acid: The most common inhibitory neurotransmitter in the central nervous system.
gamma-aminobutyric acid : A gamma-amino acid that is butanoic acid with the amino substituent located at C-4.
Pain, Intractable: Persistent pain that is refractory to some or all forms of treatment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 6.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Pain is a frequent and distressing complaint in patients with multiple sclerosis (MS) and may present a difficult therapeutic problem." | 6.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "The authors examined the safety and efficacy of intrathecal gabapentin in a randomized, blinded, placebo-controlled, multicenter trial in a heterogeneous cohort of candidates with chronic pain for intrathecal drug therapy." | 5.17 | Intrathecal gabapentin to treat chronic intractable noncancer pain. ( Coffey, RJ; Grigsby, EJ; McCarville, SE; Page, LM; Rauck, R; Schultz, DM; Wallace, MS; Webster, LR, 2013) |
| "Pregabalin 150 to 600 mg/day was effective in relieving central neuropathic pain, improving sleep, anxiety, and overall patient status in patients with spinal cord injury." | 5.12 | Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. ( Chambers, R; Cousins, MJ; Griesing, T; Murphy, TK; Otte, A; Siddall, PJ, 2006) |
| " Based on the need for new approaches in that field the effect of systemic administration of lacosamide (SPM 927, (R)-2-acetamido-N-benzyl-3-methoxypropionamide, previously referred to as harkoseride or ADD 234037), a member of a series of functionalized amino acids that were specifically synthesized as anticonvulsive drug candidates, was examined in rats in a tumor-induced bone cancer pain model and in a chemotherapy-induced neuropathic pain model." | 3.74 | Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. ( Bain, SC; Beyreuther, BK; Brot, MD; Callizot, N; Feldman, R; Stöhr, T, 2007) |
| "They had moderate to severe neuropathic pain despite treatment with gabapentin, a TCA, and a third medication (e." | 2.73 | Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. ( Dworkin, RH; Emir, B; Griesing, T; Murphy, K; Sharma, U; Stacey, BR, 2008) |
| "Gabapentin was prescribed to 60 consecutive out-patients with refractory pain persisting at four weeks or more after thoracic surgery or trauma." | 2.72 | The use of gabapentin for post-operative and post-traumatic pain in thoracic surgery patients. ( Lee, TW; Sihoe, AD; Thung, KH; Wan, IY; Yim, AP, 2006) |
| "The mean duration of pre-treatment refractory pain was 5." | 2.72 | The use of gabapentin for post-operative and post-traumatic pain in thoracic surgery patients. ( Lee, TW; Sihoe, AD; Thung, KH; Wan, IY; Yim, AP, 2006) |
| "Chest wall paresthesia distinguishable from wound pain was relieved in 24 (75." | 2.72 | The use of gabapentin for post-operative and post-traumatic pain in thoracic surgery patients. ( Lee, TW; Sihoe, AD; Thung, KH; Wan, IY; Yim, AP, 2006) |
| "To evaluate pregabalin in central neuropathic pain associated with spinal cord injury." | 2.72 | Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. ( Chambers, R; Cousins, MJ; Griesing, T; Murphy, TK; Otte, A; Siddall, PJ, 2006) |
| "Gabapentin was administered as an "add on" therapy to 22 patients with neuropathic cancer pain only partially responsive to opioid therapy." | 2.69 | Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. ( Caraceni, A; De Conno, F; Martini, C; Zecca, E, 1999) |
| "Gabapentin (Neurontin) is a new generation antiepileptic drug which appears to be advantageous in treatment of intractable pain of reflex sympathetic dystrophy." | 2.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Pain is a frequent and distressing complaint in patients with multiple sclerosis (MS) and may present a difficult therapeutic problem." | 2.68 | Open label gabapentin treatment for pain in multiple sclerosis. ( Houtchens, MK; Richert, JR; Rose, JW; Sami, A, 1997) |
| "Opioid-induced hyperalgesia has recently been described as representing a challenge for physicians in the clinical setting." | 2.50 | Managing difficult pain conditions in the cancer patient. ( Mercadante, S, 2014) |
| "Whereas most pain due to cancer can be relieved with relatively simple methods using oral analgesics, as suggested by WHO guidelines, some patients may have difficult pain situations that require more complex approaches." | 2.50 | Managing difficult pain conditions in the cancer patient. ( Mercadante, S, 2014) |
| " We performed unilateral ventralis caudalis deep brain stimulation combined with stereotactic bilateral cingulotomy to maximize the effects of treatment for 3 patients with intractable post-stroke pain." | 1.38 | Impact of ventralis caudalis deep brain stimulation combined with stereotactic bilateral cingulotomy for treatment of post-stroke pain. ( Chang, JW; Chang, WS; Kim, JP; Park, YS, 2012) |
| "Stroke is the third leading cause of death worldwide." | 1.38 | Impact of ventralis caudalis deep brain stimulation combined with stereotactic bilateral cingulotomy for treatment of post-stroke pain. ( Chang, JW; Chang, WS; Kim, JP; Park, YS, 2012) |
| "We have modified the method to a T10 spinal cord contusion model (SCC) of at-level central neuropathic pain in Sprague-Dawley rats." | 1.37 | Pregabalin attenuates place escape/avoidance behavior in a rat model of spinal cord injury. ( Baastrup, C; Finnerup, NB; Jensen, TS, 2011) |
| "In the vincristine-induced neuropathic pain model, lacosamide attenuated thermal allodynia, on the cold plate (4 degrees C), at 10 and 30 mg/kg, and in the warm (38 degrees C) and hot plate (52 degrees C) even at 3 mg/kg." | 1.34 | Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain. ( Bain, SC; Beyreuther, BK; Brot, MD; Callizot, N; Feldman, R; Stöhr, T, 2007) |
| "Gabapentin, which has been suggested as an adjuvant analgesic for neuropathic pain introduced orally, rapidly and significantly alleviated his pain and we could subsequently dispense with ketamine and mexiletine." | 1.34 | [Gabapentin mitigates neuropathic pain in cancer patients--a case report]. ( Okada, M; Shinjo, T, 2007) |
| "His neuropathic pain was not sufficiently responsive to the combination therapy of opioids, non-steroidal antiinflammatory drugs (NSAIDs), continuous infusion of subcutaneous ketamine and oral mexiletine." | 1.34 | [Gabapentin mitigates neuropathic pain in cancer patients--a case report]. ( Okada, M; Shinjo, T, 2007) |
| " A flexible dosing approach appears appropriate to ensure patient compliance and treatment success." | 1.34 | Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. ( Freynhagen, R; Grond, S; Hagebeuker, A; Junker, U; Konrad, C; Schmelz, M; Schüpfer, G; Von Giesen, HJ; Wagner, KJ; Ziegler, D, 2007) |
| "Four were cancer patients and one suffered from neuropathic pain in the neck (C3)." | 1.33 | Experience with gabapentin for neuropathic pain in adolescents: report of five cases. ( Butkovic, D; Mihovilovic-Novak, B; Toljan, S, 2006) |
| "Gabapentin has been shown to be useful in treatment of different conditions which may be caused by increased neuronal excitability." | 1.32 | Treatment of chronic neuropathic pain after traumatic central cervical cord lesion with gabapentin. ( Haller, H; Leblhuber, F; Schmidhammer, R; Trenkler, J, 2003) |
| "Gabapentin was effective in approximately 50% of pretreated patients with intractable pain." | 1.31 | [Gabapentin in the treatment of chronic intractable pain]. ( Gustorff, B; Kress, HG; Nahlik, G; Spacek, A, 2002) |
| "Gabapentin has been shown to reduce pain associated with diabetic neuropathia and postherpetic neuralgia." | 1.31 | [Gabapentin in the treatment of chronic intractable pain]. ( Gustorff, B; Kress, HG; Nahlik, G; Spacek, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.13) | 18.7374 |
| 1990's | 3 (9.38) | 18.2507 |
| 2000's | 20 (62.50) | 29.6817 |
| 2010's | 8 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rauck, R | 1 |
| Coffey, RJ | 1 |
| Schultz, DM | 1 |
| Wallace, MS | 1 |
| Webster, LR | 1 |
| McCarville, SE | 1 |
| Grigsby, EJ | 1 |
| Page, LM | 1 |
| Pérez, C | 1 |
| Navarro, A | 1 |
| Saldaña, MT | 1 |
| Masramón, X | 1 |
| Pérez, M | 1 |
| Rejas, J | 2 |
| Mercadante, S | 1 |
| Dwyer, JP | 1 |
| Jayasekera, C | 1 |
| Nicoll, A | 1 |
| Güler, S | 1 |
| Yavuz, S | 1 |
| Nakuş, E | 1 |
| Doğru, Y | 1 |
| Taira, T | 1 |
| Okabe, T | 1 |
| Sato, C | 1 |
| Matsumoto, K | 1 |
| Ozawa, H | 1 |
| Sakamoto, A | 1 |
| Baastrup, C | 1 |
| Jensen, TS | 1 |
| Finnerup, NB | 1 |
| Gordon, J | 1 |
| Lister, S | 1 |
| Prettyjohns, M | 1 |
| McEwan, P | 1 |
| Tetlow, A | 1 |
| Gabriel, Z | 1 |
| Kim, JP | 1 |
| Chang, WS | 1 |
| Park, YS | 1 |
| Chang, JW | 1 |
| Eisenberg, E | 1 |
| Brecker, C | 1 |
| Carter, AC | 1 |
| Nicholas, JJ | 1 |
| Haller, H | 1 |
| Leblhuber, F | 1 |
| Trenkler, J | 1 |
| Schmidhammer, R | 1 |
| Lalwani, K | 1 |
| Shoham, A | 1 |
| Koh, JL | 1 |
| McGraw, T | 1 |
| Lambert, G | 1 |
| Elam, M | 1 |
| Friberg, P | 1 |
| Lundborg, C | 1 |
| Gao, S | 1 |
| Bergquist, J | 1 |
| Nitescu, P | 1 |
| Butkovic, D | 1 |
| Toljan, S | 1 |
| Mihovilovic-Novak, B | 1 |
| Sihoe, AD | 1 |
| Lee, TW | 1 |
| Wan, IY | 1 |
| Thung, KH | 1 |
| Yim, AP | 1 |
| Ribera, MV | 1 |
| Ruiz, M | 1 |
| Masrramón, X | 1 |
| Pandey, CK | 1 |
| Patra, P | 1 |
| Pant, KC | 1 |
| Singh, PK | 1 |
| Siddall, PJ | 1 |
| Cousins, MJ | 1 |
| Otte, A | 1 |
| Griesing, T | 2 |
| Chambers, R | 1 |
| Murphy, TK | 1 |
| Wolfe, SQ | 1 |
| Garg, M | 1 |
| Cumberbatch, NM | 1 |
| Furst, C | 1 |
| Martinez, M | 1 |
| Hernandez, M | 1 |
| Reimers, R | 1 |
| Berrocal, Y | 1 |
| Gómez-Marín, O | 1 |
| Eaton, MJ | 1 |
| Beyreuther, BK | 1 |
| Callizot, N | 1 |
| Brot, MD | 1 |
| Feldman, R | 1 |
| Bain, SC | 1 |
| Stöhr, T | 1 |
| Okon, T | 1 |
| Okada, M | 1 |
| Shinjo, T | 1 |
| Freynhagen, R | 1 |
| Grond, S | 1 |
| Schüpfer, G | 1 |
| Hagebeuker, A | 1 |
| Schmelz, M | 1 |
| Ziegler, D | 1 |
| Von Giesen, HJ | 1 |
| Junker, U | 1 |
| Wagner, KJ | 1 |
| Konrad, C | 1 |
| Stacey, BR | 1 |
| Dworkin, RH | 1 |
| Murphy, K | 1 |
| Sharma, U | 1 |
| Emir, B | 1 |
| Bonkowsky, HL | 1 |
| Schady, W | 1 |
| Rosner, H | 1 |
| Rubin, L | 1 |
| Kestenbaum, A | 1 |
| Houtchens, MK | 1 |
| Richert, JR | 1 |
| Sami, A | 1 |
| Rose, JW | 1 |
| Caraceni, A | 1 |
| Zecca, E | 1 |
| Martini, C | 1 |
| De Conno, F | 1 |
| Frijns, PD | 1 |
| Gustorff, B | 1 |
| Nahlik, G | 1 |
| Spacek, A | 1 |
| Kress, HG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Double Blind, Placebo-controlled, Dose Response Study of Intraspinal Gabapentin (MDT2004) in Subjects With Chronic, Intractable Pain.[NCT00414466] | Phase 2 | 254 participants (Actual) | Interventional | 2006-12-31 | Terminated (stopped due to Study closed and subject follow-up completed following analysis of blinded study data.) | ||
| Pain Phenotyping of Patients With Bone Cancer Pain[NCT03908853] | 70 participants (Anticipated) | Observational | 2019-02-05 | Recruiting | |||
| Cannabinoids and an Anti-inflammatory Diet for the Treatment of Neuropathic Pain After Spinal Cord Injury[NCT04057456] | Phase 3 | 140 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used[NCT02693821] | Phase 4 | 122 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Average pain score calculated over last 7 days of baseline minus average pain score calculated over last 7 days of follow-up using the Numeric Pain Rating Scale where 0=no pain, 10=worst possible pain. (NCT00414466)
Timeframe: Baseline and Post-randomization Day 22
| Intervention | Scores on a scale (Mean) |
|---|---|
| 1 Placebo | 0.48 |
| 2 Gabapentin Low | 0.40 |
| 3 Gabapentin Medium | 0.10 |
| 4 Gabapentin High | -0.02 |
Evaluation of adverse event profiles between placebo and active treatment groups. (NCT00414466)
Timeframe: Randomization to Post-randomization Day 29 (includes dose reduction)
| Intervention | Participants (Number) |
|---|---|
| 1 Placebo | 40 |
| 2 Gabapentin Low | 32 |
| 3 Gabapentin Medium | 37 |
| 4 Gabapentin High | 36 |
Responders were subjects that reported at least a 30% decrease in average daily pain scores between baseline and Day 22. (NCT00414466)
Timeframe: Baseline to Post-randomization Day 22
| Intervention | Participants (Number) |
|---|---|
| 1 Placebo | 4 |
| 2 Gabapentin Low | 4 |
| 3 Gabapentin Medium | 1 |
| 4 Gabapentin High | 2 |
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 0 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 0 |
| Ketamine 1.5 mg/kg/Dose | 0 |
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
| Intervention | ng/mL (Mean) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 37.5 |
| Ketamine 0.5 mg/kg/Dose | 135 |
| Ketamine 1 mg/kg/Dose | 250 |
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 3 |
| Ketamine 1 mg/kg/Dose | 3 |
| Ketamine 1.5 mg/kg/Dose | 1 |
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 2 |
| Ketamine 1.5 mg/kg/Dose | 0 |
5 reviews available for gamma-aminobutyric acid and Pain, Intractable
| Article | Year |
|---|---|
Managing difficult pain conditions in the cancer patient.
Topics: Amines; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Breakthrough Pain; Cyclohexanec | 2014 |
Analgesia for the cirrhotic patient: a literature review and recommendations.
Topics: Acetaminophen; Amines; Analgesics; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2014 |
[Chronic intrathecal drug administration for the control of intractable pain].
Topics: Amines; Analgesics, Opioid; Anesthetics, Local; Baclofen; Calcium Channel Blockers; Clonidine; Cyclo | 2008 |
Ketamine: an introduction for the pain and palliative medicine physician.
Topics: Adult; Amines; Analgesics; Analgesics, Opioid; Central Nervous System; Cryoglobulinemia; Cyclohexane | 2007 |
Neurologic manifestations of acute porphyria.
Topics: Acute Disease; Aminolevulinic Acid; Animals; Central Nervous System; Depression; Electrophysiology; | 1982 |
9 trials available for gamma-aminobutyric acid and Pain, Intractable
| Article | Year |
|---|---|
Intrathecal gabapentin to treat chronic intractable noncancer pain.
Topics: Adult; Aged; Amines; Analgesics; Chronic Pain; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2013 |
Acute response to intracisternal bupivacaine in patients with refractory pain of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anesthetics, Local; Biogenic Monoamines; Blood Pressure; Brain Stem; | 2006 |
The use of gabapentin for post-operative and post-traumatic pain in thoracic surgery patients.
Topics: Adult; Aged; Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; | 2006 |
Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain.
Topics: Adult; Aged; Amines; Analgesics; Anxiety; Cyclohexanecarboxylic Acids; Depression; Disability Evalua | 2007 |
Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial.
Topics: Adult; Affect; Aged; Aged, 80 and over; Analgesics; Anxiety; Disability Evaluation; Dose-Response Re | 2006 |
Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial.
Topics: Analgesics; Diabetic Neuropathies; Double-Blind Method; gamma-Aminobutyric Acid; Humans; Neuralgia; | 2008 |
Gabapentin adjunctive therapy in neuropathic pain states.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Facial Pain; Female; Gabapen | 1996 |
Open label gabapentin treatment for pain in multiple sclerosis.
Topics: Acetates; Adult; Aged; Amines; Analgesics; Anticonvulsants; Cyclohexanecarboxylic Acids; Female; Gab | 1997 |
Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain.
Topics: Acetates; Adolescent; Adult; Aged; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Cyclohexane | 1999 |
18 other studies available for gamma-aminobutyric acid and Pain, Intractable
| Article | Year |
|---|---|
Clinical and resource utilization patterns in patients with refractory neuropathic pain prescribed pregabalin for the first time in routine medical practice in primary care settings in Spain.
Topics: Adult; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Health Care Costs; Humans; Male; Middle Ag | 2013 |
[A case of painful legs and moving toes syndrome treated with gabapentin].
Topics: Administration, Oral; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diagnosis, Differential; Fema | 2016 |
Electroconvulsive stimulation (ECS) increases the expression of neuropeptide Y (NPY) in rat brains in a model of neuropathic pain: a quantitative real-time polymerase chain reaction (RT-PCR) study.
Topics: Animals; Brain; Brain Chemistry; Disease Models, Animal; Electroconvulsive Therapy; gamma-Aminobutyr | 2009 |
Pregabalin attenuates place escape/avoidance behavior in a rat model of spinal cord injury.
Topics: Analgesics; Animals; Anxiety; Avoidance Learning; Behavior, Animal; Disease Models, Animal; Fear; Fe | 2011 |
A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain.
Topics: Analgesics; Cost-Benefit Analysis; Female; gamma-Aminobutyric Acid; Humans; Male; Neuralgia; Pain, I | 2012 |
Impact of ventralis caudalis deep brain stimulation combined with stereotactic bilateral cingulotomy for treatment of post-stroke pain.
Topics: Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Deep Brain Stimulation; | 2012 |
Lumbar spinal cord stimulation for cervical-originated central pain: a case report.
Topics: Acetates; Amines; Antidepressive Agents, Tricyclic; Cervical Vertebrae; Cyclohexanecarboxylic Acids; | 2002 |
The importance of the complete history in the discovery of a potential suicide: a case report.
Topics: Acetates; Amines; Analgesics, Opioid; Anti-Anxiety Agents; Anti-Bacterial Agents; Cyclohexanecarboxy | 2003 |
Treatment of chronic neuropathic pain after traumatic central cervical cord lesion with gabapentin.
Topics: Acetates; Amines; Amitriptyline; Analgesics; Arm; Carbamazepine; Central Cord Syndrome; Cervical Ver | 2003 |
Use of oxcarbazepine to treat a pediatric patient with resistant complex regional pain syndrome.
Topics: Amines; Amitriptyline; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; | 2005 |
Experience with gabapentin for neuropathic pain in adolescents: report of five cases.
Topics: Adolescent; Amines; Analgesics; Child; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminob | 2006 |
Gabapentin for the treatment of refractory dysesthetic pain after open cholecystectomy.
Topics: Amines; Analgesics; Cholecystectomy; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Aci | 2006 |
Optimizing the transplant dose of a human neuronal cell line graft to treat SCI pain in the rat.
Topics: Animals; Brain Tissue Transplantation; Cell Count; Cell Differentiation; Cell Line; gamma-Aminobutyr | 2007 |
Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain.
Topics: Acetamides; Amines; Analgesics; Animals; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Cyclohex | 2007 |
[Gabapentin mitigates neuropathic pain in cancer patients--a case report].
Topics: Adenocarcinoma; Amines; Analgesics; Bone Neoplasms; Cyclohexanecarboxylic Acids; Gabapentin; gamma-A | 2007 |
Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine.
Topics: Adult; Aged; Analgesics; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Pain Measuremen | 2007 |
[Pharmacotherapy for neuropathic pain caused by injury to the afferent nerve fibers].
Topics: Acetates; Amines; Analgesics, Non-Narcotic; Cyclohexanecarboxylic Acids; Drug Approval; Gabapentin; | 2001 |
[Gabapentin in the treatment of chronic intractable pain].
Topics: Acetates; Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non | 2002 |